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Abstract
Background: Hypertension is a major risk factor for cardiovascular disease (CVD), yet treatment and control rates
for hypertension are very low in low- and middle-income countries (LMICs). Lack of effective referral networks
between different levels of the health system is one factor that threatens the ability to achieve adequate blood
pressure control and prevent CVD-related morbidity. Health information technology and peer support are two
strategies that have improved care coordination and clinical outcomes for other disease entities in other settings;
however, their effectiveness and cost-effectiveness in strengthening referral networks to improve blood pressure
control and reduce CVD risk in low-resource settings are unknown.
Methods/design: We will use the PRECEDE-PROCEED framework to conduct transdisciplinary implementation
research, focused on strengthening referral networks for hypertension in western Kenya. We will conduct a baseline
needs and contextual assessment using a mixed-methods approach, in order to inform a participatory, community-
based design process to fully develop a contextually and culturally appropriate intervention model that combines
health information technology and peer support. Subsequently, we will conduct a two-arm cluster randomized trial
comparing 1) usual care for referrals vs 2) referral networks strengthened with our intervention. The primary
outcome will be one-year change in systolic blood pressure. The key secondary clinical outcome will be CVD risk
reduction, and the key secondary implementation outcomes will include referral process metrics such as referral
appropriateness and completion rates. We will conduct a mediation analysis to evaluate the influence of changes in
referral network characteristics on intervention outcomes, a moderation analysis to evaluate the influence of
baseline referral network characteristics on the effectiveness of the intervention, as well as a process evaluation
using the Saunders framework. Finally, we will analyze the incremental cost-effectiveness of the intervention relative
to usual care, in terms of costs per unit decrease in systolic blood pressure, per percentage change in CVD risk
score, and per disability-adjusted life year saved.
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Discussion: This study will provide evidence for the implementation of innovative strategies for strengthening
referral networks to improve hypertension control in LMICs. If effective, it has the potential to be a scalable model
for health systems strengthening in other low-resource settings worldwide.
Trial registration: Clinicaltrials.gov, NCT03543787. Registered on 29 June 2018.
Keywords: Referral networks, Hypertension, Cardiovascular disease, Health systems, Health systems strengthening,
Implementation science, Health information technology, Peer support, Low- and middle-income countries (LMICs), Kenya
Background
Elevated blood pressure (BP) is a leading preventable
cause of cardiovascular disease (CVD) and premature
death and disability globally [1, 2]. Hypertension treat-
ment and control rates are low worldwide, but worst in
low- and middle-income countries (LMICs), where less
than 37% of patients are on treatment and 13% have ad-
equately controlled BP [3]. Interventions to strengthen
LMIC health systems to control hypertension are ur-
gently needed [4].
Most LMICs utilize a tiered health care system, span-
ning a primary, secondary, and tertiary care continuum,
with the goal of broadening access to basic health ser-
vices through decentralizing, and decongesting higher-
level facilities [5, 6]. The tiers are connected by referral
networks which enable triaged access to different levels
of care depending on patients’ needs. The effectiveness of
these networks, however, is often inadequate, character-
ized by suboptimal rates of referral completion [7–10].
Key barriers to successful referral completion include
logistical issues, cost, knowledge gaps among providers,
lack of communication across levels of care, and inability
to track referred patients [8, 11–15]. Successful referral
completion has been shown to improve CVD care in
high-income countries [16, 17] as well as HIV care in
LMICs [18, 19]. However, studies evaluating interventions
to improve referral networks for hypertension in LMICs
are lacking.
Health information technology (HIT) and peer support
target many of the barriers to successful referral comple-
tion. HIT interventions, such as electronic medical re-
cords and mobile technology in health tools (mHealth),
are a key strategy in improving patient encounter docu-
mentation, data capture, inter-provider communication,
and follow-up for non-communicable disease manage-
ment in LMICs [20–23]. Peer support approaches lever-
age the unique patient–patient interactions built on
shared disease experiences to influence behavior change
[24]. Peer navigators have been used to improve linkage
and retention in care for patients with HIV, mental
health, and cancer [25–31], and even facilitate referral
completion for cancer care [32].
The Strengthening Referral Networks for Management
of Hypertension across the Health System (STRENGTHS)
study is a cluster randomized control trial that will evalu-
ate the effectiveness and cost-effectiveness of a combined
HIT and peer support intervention on referral completion,
BP improvement, and CVD risk reduction in Kenya. The
STRENGTHS study uses a transdisciplinary implementa-
tion research approach and is the first study to rigorously




The Academic Model Providing Access to Healthcare
(AMPATH) program is an academic global health part-
nership between Moi Teaching and Referral Hospital
(MTRH), Moi University College of Health Sciences,
and a consortium of North American universities led by
Indiana University [33–35]. In recognition of the grow-
ing non-communicable disease (NCD) burden in LMICs
[36], AMPATH has established a Chronic Disease Man-
agement (CDM) Program in collaboration with the Min-
istry of Health (MOH). The CDM Program has enrolled
over 15,000 patients with hypertension at 69 facilities
spanning all levels of the health system, alongside sys-
tem-wide approaches to task redistribution, use of
mHealth and electronic decision support, and ensuring a
reliable supply of medicines for hypertension and other
NCDs [37–39]. At MTRH, there is an inpatient cardiac
critical care unit, a specialist outpatient cardiology clinic,
and advanced cardiac diagnostic services [40]. It is
within this clinical infrastructure that we plan to develop
and test our intervention.
We will conduct this study within the AMPATH
CDM program’s catchment area across eight geographic-
ally separate referral networks (Fig. 1). The Kenyan pub-
lic-sector health system functionally coalesces into the
three traditional health system levels—primary, second-
ary, and tertiary—and each referral network in our
catchment area is centered around a secondary-level
health facility: Kitale, Webuye, Kocholya, Turbo, Mosor-
iot, Burnt Forest, Bunyala, and Butula (Fig. 1). Each of
these serves as the link between the common tertiary-
level center, MTRH, staffed by specialists and sub-spe-
cialists, and several primary-level health facilities that
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feed into it, staffed by clinical officers (mid-level pro-
viders) and nurses (Fig. 1).
Aims
The purpose of this study is to use a transdisciplinary,
implementation science research approach to strengthen
referral networks to improve hypertension control and
reduce CVD risk. Our central hypothesis is that HIT in-
tegrated with peer support will be effective and cost-ef-
fective in strengthening referral networks, improving BP
control, and reducing CVD risk among patients with
hypertension in western Kenya.
The aims of the STRENGTHS study (Fig. 2) are to:
1. Conduct a baseline needs and contextual
assessment, using a mixed-methods approach, for
implementing and integrating HIT and peer
support to strengthen referral networks for
hypertension control. We will use these data to
develop a contextually and culturally appropriate
intervention using a participatory, iterative design
process.
2. Evaluate the effectiveness of HIT and peer support
for hypertension control by conducting a two-arm
cluster randomized trial comparing: 1) usual care
for referrals vs 2) referral networks strengthened
with an integrated HIT and peer support
intervention. The primary outcome will be one-year
change in systolic blood pressure (SBP). The key
secondary clinical outcome will be CVD risk
reduction, and the key secondary implementation
outcomes will include referral process metrics such
as referral appropriateness and completion rates.
We will conduct mediation and moderation
Fig. 1 AMPATH clinic sites and referral network clusters; Health system levels
Fig. 2 STRENGTHS study aims
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analyses to evaluate the interaction between referral
network characteristics and intervention outcomes.
We will also conduct a process evaluation [41].
3. Evaluate the incremental cost-effectiveness of HIT
and peer support, in terms of costs per unit
decrease in SBP, per percentage change in CVD risk
score, and per disability-adjusted life year (DALY)
saved.
Implementation framework
We are using the PRECEDE-PROCEED implementation
science conceptual framework to help guide our study
(Fig. 3) [42, 43]. We chose the PRECEDE-PROCEED
framework because of its participatory nature, multi-
pronged evaluation approach, and explicit assessment of
the multi-level factors that may affect the uptake and suc-
cess of our intervention. PRECEDE-PROCEED has also
been successful in developing interventions to promote
cardiovascular health in low-income populations [44].
Conceptual model
Both HIT and peer support may strengthen referral net-
works, improve BP control, and reduce CVD risk
through multiple mechanisms. HIT may address barriers
to hypertension control at the provider and health sys-
tem levels, by improving data quality, integrating and co-
ordinating care across levels of the health system [45],
and improving communication between providers [11].
The clinical decision support programmed into the HIT
platform may also directly lead to improvements in re-
ferral appropriateness. Peer navigators may address bar-
riers at the patient and health system levels, by helping
patients navigate health system complexity and over-
come barriers to health seeking behavior [46]. By ad-
dressing these multi-level factors, we hypothesize that
our intervention will change both the clinical environ-
ment as well as patient and provider behaviors, which, in
turn, will lead to improvements in referral network char-
acteristics and referral process metrics. This has the po-
tential to improve the coordination of care for patients
Fig. 3 PRECEDE-PROCEED implementation framework and conceptual model of change
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with hypertension across the health system, ultimately
reducing BP and CVD risk.
Baseline needs and contextual assessment and
participatory design process
We will use a mixed-methods approach to conduct a base-
line needs and contextual assessment for implementing an
integrated HIT and peer support intervention for strength-
ening referral networks for hypertension control. This will
include: 1) observational process mapping and gap assess-
ment; 2) baseline referral network analysis; and 3) a com-
bination of qualitative research methods to identify
facilitators, barriers, contextual factors, and readiness for
change that may impact implementation of the integrated
STRENGTHS intervention.
Observational process mapping, a technique adapted
from Lean Six Sigma, will be conducted in order to de-
termine patient and data flow throughout the referral
network at each level of the health system [47, 48]. We
will use a standardized checklist, adapted from the
Kenya Health Sector Referral Strategy [49], to observe
patient and data movement throughout the system, as
well as detail the personnel, supplies, equipment, and lo-
gistics necessary for the referral network to be func-
tional. To augment this, clinical staff and patients will be
recruited by purposive and snowball sampling for semi-
structured interviews in order to describe all the steps in
the referral process, understand associated costs and
how this affects referrals, clarify staff roles and responsi-
bilities, delineate data sources and mechanisms for com-
munication, and elicit perspectives on challenges and
opportunities for improving referral networks [47, 48].
A baseline referral network analysis will be conducted
by recruiting all AMPATH clinicians at every facility
participating in the trial to complete a baseline survey of
referral preferences and patterns. We will ask clinicians
to indicate other clinicians who they go to for advice,
who they discuss clinical issues with, and who they refer
patients to for hypertension care. We will also analyze
actual clinician-to-clinician referral patterns measured
from the medical record. This will form the basis of the
mediation and moderation analysis we will conduct once
the trial is completed.
Qualitative methods will involve a combination of
focus group discussions (FGDs), key informant inter-
views, and community mabaraza, conducted at each
level of the health system within each of the six referral
network clusters. Mabaraza are traditional community
assemblies in East African culture and have been used as
a novel methodology in community-based participatory
research [50, 51]. We will use purposive sampling to re-
cruit patients and clinical staff for the FGDs, and clinic
leaders and health system administrators for the key in-
formant interviews. For the mabaraza and FGDs,
discussions will be allowed to deviate from the initial guid-
ing discussion topics if additional relevant issues emerge,
and participatory techniques will be used to elicit emotional
elements and encourage group interaction. Thematic con-
tent analysis will be performed, using both deductive (a
priori) and inductive (emerging) codes. We will also assess
inter-coder reliability, and a kappa-statistic will be
calculated.
After the baseline needs and contextual assessment is
complete, we will use these data to inform a participa-
tory, iterative design process to fully develop the inte-
grated HIT and peer support STRENGTHS intervention
[52–54] A “design team” including a facilitator, research
staff, clinical staff, informatics staff, peer navigators, and
patients will be formed. The design process will involve
three phases: brainstorming, conceptualization, and cre-
ation. This design process will use the findings from the
baseline needs and contextual assessment alongside in-
put from this diverse group of stakeholders to inform
the detailed development of the integrated HIT and peer
support intervention protocol. Once the intervention
model is developed, we will conduct additional FGDs to
assess acceptability [55], as well as a 3-month pilot of
the intervention to evaluate feasibility [56].
Cluster randomized trial
We will conduct a two-arm cluster randomized trial
comparing usual care and referral networks strength-
ened with an integrated HIT and peer support inter-
vention. The primary outcome measure will be one-
year change in SBP and a key secondary outcome will
be change in CVD risk score. There will be a total of
eight clusters in the trial, four in each arm, with each
cluster in a geographically distinct referral network
within the overall AMPATH CDM program. First,
each referral network cluster will be stratified by size
of the health facility at the secondary level. Then
cluster randomization will be done within each strata.
Cluster randomization will be done using a computer-
ized random number generator in a 1:1 allocation se-
quence between intervention and control groups. One
of the investigators, separate from other research or
clinical staff, will generate the allocation sequence
and complete randomization. Study staff will then en-
roll participants in the trial. The trial flow chart is
shown in Fig. 4 and the SPIRIT figure is shown in
Fig. 5. The SPIRIT checklist is provided in
Additional file 1.
Study participants
Adult patients ≥ 18 years who are enrolled in
AMPATH’s CDM program with hypertension at any
level of care, and who meet criteria for referral up or
down the referral network, will be eligible for inclusion
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Fig. 4 Flow of cluster randomized trial
Fig. 5 STRENGTHS SPIRIT figure
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in the trial. Individual informed consent will be obtained
by study staff. Criteria for “referral up” the network is
defined as patients with hypertension who remain
uncontrolled (SBP ≥ 140 or diastolic blood pressure
(DBP) ≥ 90) on three or more anti-hypertensive medica-
tions, who have signs or symptoms of end-organ dam-
age, or who have suspected secondary causes of
hypertension. Criteria for “referral down” the network is
defined as controlled BP (SBP < 140 and DBP < 90) for
three or more consecutive visits and no evidence of
new end-organ damage. Exclusion criteria include
acute illness requiring immediate medical attention,
terminal illness, and inability to provide informed
consent.
Integrated HIT and peer support intervention
Usual care
For patients requiring referral up the network, the refer-
ring clinician writes a referral letter on a blank referral
form. This referral letter is then given to the patient,
who is responsible for presenting it to the receiving facil-
ity and arranging the referral visit. For patients requiring
referral down the network, a counter-referral letter, and/
or copies of clinical records, are given to the patient to
take back to their primary facility, although in reality this
is inconsistent.
HIT plus peer support referral intervention
Those randomized to the intervention group will receive
clinical care for hypertension in the same manner as
those randomized to the usual care group. Furthermore,
refusal to participate in the trial or withdrawal from the
trial will not affect clinical care provided. Reasons for re-
ferral will also be the same in the two groups. The
change in referral process is the intervention (Fig. 6).
Health information technology
AMPATH uses the AMPATH Medical Record System
(AMRS), a customized version of OpenMRS [22] that is
centrally hosted and accessed by tablet via the Internet.
Our HIT intervention will augment AMRS to support a
referral system in four ways: 1) communication—facili-
tate data sharing by all providers and peer navigators
across all levels of the health system; 2) decision sup-
port—provide clinical decision support to facilitate ap-
propriate patient referrals; 3) tracking—generation and
sharing of real-time patient referral lists; and 4) dash-
boards—create a platform for monitoring key referral
process metrics. The system will prompt for referral
based on clinical algorithms built into the clinical deci-
sion support, but also will allow the provider to initiate a
referral based on his/her clinical judgment. Providers
and peer-navigators will access the referral dashboard
for a clinic to review patient referrals and track the
Fig. 6 STRENGTHS intervention
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status of referred patients. Key referral process metrics,
such as referral wait times and completion rates, will be
available in real-time for providers and peer navigators
to monitor and act upon. Additional functionality of the
HIT platform will be developed from the participatory
design process described above.
Peer support
The peer support component of the intervention will in-
volve peer navigators at each level of the referral net-
work—primary, secondary, and tertiary. Peer navigators
are patients within the AMPATH CDM program who
have well-controlled hypertension; they have the shared
experience of living with hypertension and navigating
the same health system as the patients enrolled in the
trial. The peer support intervention has three main func-
tions: 1) referral adherence—enhance communication
between clinicians and patients to improve referral ad-
herence; 2) navigation—help patients navigate the com-
plex health system [30]; and 3) psychosocial support—
help patients overcome barriers to health seeking behav-
ior. Referral adherence support will help enhance com-
munication about the referral between the provider and
patient by having a peer navigator meet with patients to
review referral rationale and logistics. The second major
role of the peer navigator is health system navigation, es-
pecially at the tertiary level. Here, the peer navigator can
personally receive a referred patient and walk them
through registration, scheduling, triage, and diagnostic
work-up in order to streamline the referral process and
ensure patients are not lost in the complexity of the sys-
tem [57]. Furthermore, peer navigators will meet with
patients after the clinic visit to provide any follow-up
navigation between the pharmacy, laboratory, or im-
aging. The third major role of the peer navigator is to
provide psychosocial support, helping patients overcome
individual-level barriers to health-seeking behaviors,
drawing from the innate trust inherent in their shared
disease experience [24].
Integrated HIT plus peer support
The peer navigators will be equipped with a HIT tool, as
described above, so they can see the same data as the cli-
nicians in order to track and follow referred patients ap-
propriately. When a clinician at the primary level refers
a patient to a higher level of care, the peer navigator
covering that patient’s community catchment area will
automatically be alerted via the HIT tool so they can
contact and meet the patient and review referral logis-
tics. The peer navigator will then complete a referral
navigation form on the HIT tool, which will automatic-
ally trigger a notification to the clinician and peer navi-
gator at the receiving facility. Communication between
the peer navigators at each level of the health system will
be automated via the HIT tool to ensure seamless com-
munication and data-sharing. Peer navigators at all levels
will be trained to use the HIT tools, understand the ba-
sics of clinical referral algorithms and processes, navigate
the health system, and provide education, counseling,
motivational interviewing, and psychosocial support.
Prior to trial enrollment, all clinicians will be sensitized
about the STRENGTHS trial and educated on the
STRENGTHS intervention. This will be done to help
standardize the intervention delivery across clusters as
well as to improve adherence and fidelity to the inter-
vention model.
Outcomes
The primary outcome is one-year absolute mean change
in SBP. The BP measurement for inclusion in the trial,
and used in the primary outcome analysis, will be stan-
dardized and conducted by trained study staff. The key
secondary clinical outcome is one-year change in overall
CVD risk as measured by the QRISK2 score, which has
been validated for calculating 10-year CVD event risk
for Black Africans [58–66]. Treatment effect will be
average change in SBP and QRISK2 score from baseline
to month 12 and will be estimated using an intention-
to-treat approach with appropriately specified regression
models. Other clinical secondary outcomes will include
mortality, hospital admissions, CVD complications,
change in CVD risk factors and behaviors, and medica-
tion adherence [67]. The primary outcome and clinical
secondary outcomes pertain to the individual participant
level. We will also measure referral process metrics as
key secondary implementation outcomes, including re-
ferral completion rates, median referral completion time,
referral eligibility, referral indication, and referral appro-
priateness. Data will be collected on covariates we
hypothesize may be related to our outcomes. These in-
clude patient demographics, socioeconomic and educa-
tion status, clinical comorbidities, CVD risk factors,
health behaviors, medication adherence, geographic lo-
cation, referral level, provider level of training, and peer
navigator and provider characteristics.
Statistical power
We expect that each of the six referral networks will en-
roll at least 200 participants. Given the longstanding his-
tory of the AMPATH CDM program and robust clinical
infrastructure in our catchment area, as well as previous
success in recruiting participants for community- and
clinical-based research related to hypertension and other
chronic diseases, we anticipate being able to successfully
enroll our needed number of participants. To augment
this, we have sensitized all participating AMPATH CDM
staff on the STRENGTHS trial, and conducted training
of clinicians on the AMPATH CDM hypertension
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treatment and referral guidelines. Through our baseline
needs and contextual assessment (Aim 1), clinic staff
have become well versed on the eligibility criteria and
enrollment procedures, which will also help with recruit-
ment for the trial. During our pilot testing, if we en-
counter difficulty with recruitment or enrollment, then
we will put additional strategies in place to overcome
this. We estimate a 10-mmHg reduction in SBP in the
intervention arm compared to the usual care arm [68].
For our power calculation, we set the type I and type II
error rates at 5% and 20%, respectively. We account for
within-cluster correlation using intra-class correlation
(ICC) values ranging from 0.02 to 0.06 consistent with
prior studies using SBP as the outcome [69]. We analyze
scenarios over a range of minimum detectable differ-
ences (MDD) assuming a standard deviation (SD) for
change in SBP of 15 from the literature, with SD ranges
from 10 to 20 [69, 70]. Finally, we assume that up to
15% of enrolled participants will be lost to follow-up.
Table 1 presents expected power assuming a standard
deviation of 15 for the comparison across different com-
binations of ICC and minimum detectable differences
(MDD). Over a wide range of plausible ICC, with stand-
ard deviation fixed at 15, we will be able to detect a
mean difference in change in SBP consistent with the
published literature [69, 70] and our preliminary data
[71, 72] with power greater than 80%.
Analytical approach
We will use an analysis of covariance model with cluster
effects to estimate and draw inference about treatment
effects for both primary and key secondary outcomes.
The model specification is:
yij ¼ αþ γ j þ β1xij þ θbij þ eij
where yij is SBP at the end of follow-up for the ith indi-
vidual in the jth cluster, bij is baseline SBP, and the indi-
cators xij represent intervention group membership, with
usual care as the reference. Hence, β coefficient repre-
sents the difference in mean change in SBP between
usual care and the intervention. The intercept is α and γj
is the effect of the jth cluster. Cluster effects γj will ini-
tially be modeled as fixed effects, but we will use a
mixed model structure and assign a normal distribution
if the data support this assumption. We will compare
key independent variables across the trial arms to ensure
balance of the randomization process and adjust the
model to estimate treatment effects as needed. For mod-
eling QRISK2, we will use the transformation log(−log
(QRISK2)) because the risk score ranges from 0% to
100% [73]. We will test the further hypotheses that
changes in referral network characteristics and referral
process metrics can mediate the effect of the interven-
tion on CVD outcomes, and that baseline referral net-
work characteristics can moderate the effect of the
intervention on outcomes, by conducting a mediation
and moderation analysis, respectively [74, 75]. Further
details of the data management procedures and statis-
tical methods, including approach to missing data, medi-
ation and moderation analysis, and secondary outcomes,
are available upon request from the authors.
Process evaluation
We will use the Saunders Framework [41] to conduct
a process evaluation of the integrated HIT and peer
support intervention. This process evaluation will be
undertaken in order to monitor program implementa-
tion and better understand the relationship between
intervention components and health outcomes. The
Saunders Framework provides a systematic approach
for guiding the evaluation of key implementation
process measures across the following domains: fidel-
ity (quality), dose delivered (completeness), dose re-
ceived (exposure and satisfaction), recruitment, reach
(participation rate), and context. Mixed quantitative
and qualitative methods will be used to collect data
from study participants and clinical staff, as well as
from study and clinical encounter forms. This process
evaluation will generate both formative and summa-
tive data [76, 77].
A combination of quantitative and qualitative ap-
proaches will be taken, including observation forms,
checklists, surveys, record review, focus group discus-
sions, and semi-structured interviews. Study participants,
clinical staff, and study and clinical encounter forms will
be the sources of data. Descriptive statistics will be gen-
erated for quantitative data, and thematic content ana-
lysis will be performed for qualitative data. Formative
data will be reported iteratively to the study team and
staff throughout the trial, while summative data will be
reported at the end of the trial.
Cost-effectiveness analysis
We will evaluate the incremental cost-effectiveness of
HIT and peer support in terms of costs per unit
Table 1 Estimated power over a range of ICC and MDD values
MDD ICC
0.02 0.03 0.04 0.05 0.06
4 36 27 22 19 17
6 65 51 42 36 32
8 87 74 64 56 50
10 96 89 82 74 67
12 99 97 92 87 82
14 99 99 98 95 91
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change in SBP, per percentage change in CVD risk
score, and per DALY saved. For each intervention
arm, costs and potential cost offsets from the societal
and payer perspectives will be captured using previ-
ously validated cost questionnaires used in Kenya for
hypertension trials [78–80]. Study participants will
complete one costing instrument, capturing healthcare
utilization and expenditures, work loss, and transpor-
tation costs. All measures of burden will be mone-
tized and, if there are differences across arms, used to
quantify cost offsets from intervention delivery. Re-
search staff will complete an additional costing instru-
ment in order to capture all relevant labor, materials,
supplies, and contracted services costs for all intervention
activities. Only net incremental costs, after removing sunk
costs and after factoring in cost offsets, will be included as
the numerator in the cost-effectiveness analysis as these
are the relevant costs for decision makers. We will also
identify which activities drive the overall costs, and how
costs would change if specific activities are added or elimi-
nated. Effectiveness in terms of SBP and CVD risk score
will be defined as above. DALY improvements will be esti-
mated using well-defined relationships between blood
pressure reductions and CVD DALYs averted [81]. We
will also conduct sensitivity analyses to gauge the influ-
ence of key assumptions on the resulting incremental
cost-effectiveness ratio.
Discussion
The burden of hypertension and CVD in LMICs is
immense, requiring a coordinated health system re-
sponse. Ineffective referral networks in LMICs con-
tribute substantially to CVD-related morbidity and
mortality. The STRENGTHS study has been designed
to strengthen referral networks in order to improve
BP control and reduce CVD risk. The STRENGTHS
study offers several innovative elements with some
key advantages. First, while HIT and peer support are
proven interventions to improve coordination of care
and health outcomes, their application in an inte-
grated fashion to address multi-level factors in order
to improve referral networks for BP control and CVD
risk reduction in LMICs is novel. Second, we are using
a participatory design process to ensure our intervention
model is culturally appropriate, context-specific, and re-
sponsive to community needs and local health system
realities. Third, we use PRECEDE-PROCEED, applying an
implementation science theoretical framework to guide
our study. Fourth, we are evaluating for the possible medi-
ating and moderating influence of referral network char-
acteristics on intervention outcomes, as well as including
a rigorous cost effectiveness analysis. Fifth, we are a team
of transdisciplinary investigators with expertise in cardi-
ology, internal medicine, pharmaceutical care, health
systems, economics, informatics, social network analysis,
qualitative methods, biostatistics, and implementation sci-
ence. Finally, we are layering this implementation research
approach onto the existing clinical care system, maximiz-
ing the likelihood, if successful, for continued adoption
and sustainability. While this research is situated within a
particular health system in a single country focused on a
single disease outcome, we anticipate that both the meth-
odology and results can be applied to other settings.
Our study has some limitations and challenges.
First, our baseline needs and contextual assessment
is critical to designing our intervention model and
implementing our trial, and there may be resistance
by the community to participation. To mitigate this,
we will hold sensitization sessions among clinic staff
and patients before initiation, and we have been suc-
cessful with this approach in previous studies in this
setting [50, 51, 82]. Second, we are conducting a
two-arm trial with a combined (HIT plus peer sup-
port) intervention group, rather than a four-arm trial
studying each individual intervention component,
plus a separate combined group. We will therefore
not be able to determine which component of the
intervention was responsible for the observed effects
on the primary and secondary outcomes. We chose
this approach because a four-arm trial, randomized
at the level of the referral network cluster, would be
difficult to power and logistically complex to imple-
ment in the context of the existing care program.
Our process evaluation will help to elucidate which
components of the intervention worked, and how
they performed on key implementation measures. A
third limitation is that blinding of the study partici-
pants and research staff is not possible due to the
design of the intervention. This may lead to bias, al-
though we do not anticipate this to be a major issue
given integration into the existing care system and
the geographically distinct clusters. Despite these
limitations, we anticipate that the STRENGTHS
study will generate important results and provide a
scalable health systems intervention for chronic dis-
eases globally.
Trial status
The study-specific manual of operations and policies
have been developed, and training of research and
clinical care staff is being completed. The Data Safety
and Monitoring Board has been formed. The baseline
needs and contextual assessment of Aim 1 has been
completed and data analysis is underway. Enrollment
into the trial is planned to start in August 2019 and
be completed by July 2010. This is study protocol
version 6.0 and the version date is May 6, 2019.
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